[go: up one dir, main page]

PE20030978A1 - Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico - Google Patents

Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico

Info

Publication number
PE20030978A1
PE20030978A1 PE2003000086A PE2003000086A PE20030978A1 PE 20030978 A1 PE20030978 A1 PE 20030978A1 PE 2003000086 A PE2003000086 A PE 2003000086A PE 2003000086 A PE2003000086 A PE 2003000086A PE 20030978 A1 PE20030978 A1 PE 20030978A1
Authority
PE
Peru
Prior art keywords
pyridin
amino
phenoxy
methyl
terc
Prior art date
Application number
PE2003000086A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Chandra Aggarwal Prakash
Bruce Allen Lefker
Kim Anne Johnson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030978A1 publication Critical patent/PE20030978A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE REFIERE A COMPUESTOS COMO ACIDO 2-(4-{[(3-CARBOXIMETOXIBENCIL)-(PIRIDIN-3-SULFONIL)-AMINO]-METIL} FENIL)-2-METILPROPIONICO, ACIDO (3-{[(4-(2-HIDROXI-1,1-DIMETILETIL)BENCIL)-(PIRIDIN-3-SULFONIL)AMINO]METIL} FENOXI)ACETICO, ACIDO (3-{[(4-TERC-BUTILBENCIL)-(PIRIDIN-N-OXIDO-3-SULFONIL)-AMINO]-METIL} FENOXI)-ACETICO. ACIDO (5-{[(4-TERC-BUTILBENCIL)-(PIRIDIN-3-SULFONIL)-AMINO]-METIL} HIDROXIFENOXI)ACETICO. SE REFIERE TAMBIEN AL COMPUESTO ACIDO 2-{4-[PIRIDIN-N-OXIDO-3-SULFONILAMINO)METIL]FENIL}-2-METIL-PROPIONICO, GLUCORONICO DEL ACIDO (3-{[(4-(2-HIDROXI-1,1-DIMETILETIL)BENCIL)-(PIRIDIN-3-SULFONIL)AMINO]METIL} FENOXI)ACETICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE OSTEOPOROSIS
PE2003000086A 2002-01-31 2003-01-28 Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico PE20030978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31

Publications (1)

Publication Number Publication Date
PE20030978A1 true PE20030978A1 (es) 2003-11-19

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000086A PE20030978A1 (es) 2002-01-31 2003-01-28 Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico

Country Status (29)

Country Link
US (1) US6852863B2 (es)
EP (1) EP1470109A1 (es)
JP (1) JP2005521668A (es)
KR (1) KR20040077884A (es)
CN (1) CN1625549A (es)
AP (1) AP2004003094A0 (es)
AR (1) AR038332A1 (es)
BR (1) BR0307339A (es)
CA (1) CA2473984A1 (es)
EA (1) EA200400724A1 (es)
EC (1) ECSP045215A (es)
GB (1) GB2400100B (es)
HN (1) HN2003000051A (es)
HR (1) HRP20040683A2 (es)
HU (1) HUP0500012A2 (es)
IL (1) IL162167A0 (es)
IS (1) IS7281A (es)
MA (1) MA27169A1 (es)
MX (1) MXPA04004960A (es)
NO (1) NO20043569L (es)
OA (1) OA12760A (es)
PA (1) PA8564601A1 (es)
PE (1) PE20030978A1 (es)
PL (1) PL371982A1 (es)
TN (1) TNSN04138A1 (es)
TW (1) TW200302080A (es)
UY (1) UY27632A1 (es)
WO (1) WO2003064391A1 (es)
ZA (1) ZA200404067B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US7666330B2 (en) * 2005-04-20 2010-02-23 Lg Chem, Ltd. Additive for non-aqueous electrolyte and secondary battery using the same
BRPI0714683A2 (pt) * 2006-07-28 2013-03-26 Pfizer Prod Inc agonistas ep2
CN101669030B (zh) 2007-03-08 2016-01-13 小利兰·斯坦福大学托管委员会 线粒体醛脱氢酶2调节剂和其使用方法
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
WO2009113600A1 (ja) * 2008-03-12 2009-09-17 宇部興産株式会社 ピリジルアミノ酢酸化合物
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
CA2757291C (en) 2009-03-30 2017-05-23 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of glaucoma
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
IL162167A0 (en) 2005-11-20
GB2400100B (en) 2006-04-12
HN2003000051A (es) 2003-09-24
CA2473984A1 (en) 2003-08-07
AP2004003094A0 (en) 2004-09-30
US20030216445A1 (en) 2003-11-20
NO20043569D0 (no) 2004-08-26
US6852863B2 (en) 2005-02-08
EA200400724A1 (ru) 2004-12-30
WO2003064391A1 (en) 2003-08-07
PL371982A1 (en) 2005-07-11
OA12760A (en) 2006-07-04
TW200302080A (en) 2003-08-01
GB2400100A (en) 2004-10-06
UY27632A1 (es) 2003-08-29
HUP0500012A2 (hu) 2005-04-28
ZA200404067B (en) 2005-08-29
PA8564601A1 (es) 2003-09-05
MA27169A1 (fr) 2005-01-03
TNSN04138A1 (fr) 2007-03-12
KR20040077884A (ko) 2004-09-07
NO20043569L (no) 2004-08-26
EP1470109A1 (en) 2004-10-27
ECSP045215A (es) 2004-09-28
HRP20040683A2 (en) 2004-10-31
GB0413967D0 (en) 2004-07-28
AR038332A1 (es) 2005-01-12
BR0307339A (pt) 2004-12-07
CN1625549A (zh) 2005-06-08
MXPA04004960A (es) 2005-04-08
JP2005521668A (ja) 2005-07-21
IS7281A (is) 2004-05-21

Similar Documents

Publication Publication Date Title
PE20030978A1 (es) Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
PE20040516A1 (es) Derivados de 1,2-azol
TW200716610A (en) Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
NZ601786A (en) Novel compounds and compositions and methods of use
TW200716107A (en) Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
NZ593906A (en) Gpr120 receptor agonists and uses thereof
NO20080942L (no) Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE)
PE20060825A1 (es) Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
BR0306559A (pt) Forma de aplicação oral para etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-ben-zimidazol-5-carbonil)-piridin- 2-il-amino]-propiÈnico e seus sais
RU2010150911A (ru) Амидное соединение
NZ614305A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
WO2009041705A3 (en) 5-membered heterocyclic compounds as proton pump inhibitors
WO2007096889A3 (en) Process for preparing montelukast and salts thereof
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina
NO20074303L (no) 7-{4-[2-(2,6-diklor-4-metylfenoksy)etoksy]fenyl}-3,9-diazabisyklo-[3.3.1]non-6-en-6-karboksylsyresyklopropyl-(2,3-dimetylbenzyl)amid som renininhibitor til behandling av hypertensjon
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PH12022550380A1 (en) Salt
FR2898885B1 (fr) Compose a base de disphosphate de titane et de carbone, procede de preparation et utilisation comme materiau actif d'une electrode pour accumulateur au lithium.
AR112464A1 (es) Forma cristalina de ácido (2s)-2-[[(z)-[1-(2-amino-4-tiazolil)-2-[[(3s)-2,2-dimetil-4-oxo-1-(sulfoxi)-3-azetidinil]amino]-2-oxoetiliden]amino]oxi]-3-[4-[imino[(3r)-3-piperidinilamino]metil]fenoxi]-propanoico
PT1701722E (pt) Sal do ácido n-hidroxi-4-{5-[4-(5-isopropil-2-metil-1,3-tiazol- 4-il)fenoxi]pentoxi}benzamidina-2-metanossulfónico

Legal Events

Date Code Title Description
FD Application declared void or lapsed